ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novo Nordisk is using some of the profit from its weight-loss drugs to form a partnership with Neomorph, a start-up backed by Deerfield Management. The Danish firm will pay Neomorph an unspecified amount up front and up to $1.46 billion in milestone payments across multiple targets. The drugs in the collaboration are molecular glues—small molecules that degrade harmful proteins. Neomorph launched in late 2020 with $109 million to develop such treatments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter